The 15th Five-Year Plan Leads the High-Quality Development of the Health Processing Industry

In 2026, the Outline of the 15th Five-Year Plan for National Economic and Social Development of the People's Republic of China was officially implemented. The "Healthy China" strategy has been elevated to a higher position, clearly proposing the implementation of a health-first development strategy, promoting the shift from a disease-centered model to a health-centered model, and fostering the growth of health consumption, charting a clear path for the high-quality development of the health industry. As a core hub in the health industry chain, the contract manufacturing (OEM/ODM) sector connects upstream raw material suppliers and downstream brand terminals. Driven by policy dividends, market upgrading, and technological innovation, it is  extensive growth and entering a new stage of standardized, intelligent, and diversified development. As a benchmark enterprise in the industry, Zhengzhou Linnuo Pharmaceutical will ride this momentum to build a new health industry ecosystem together with the sector.

The 15th Five-Year Plan explicitly lists biomedicine and life health as strategic emerging industries, with supporting policies continuously tilted toward the health sector. It not only increases investment in health care for the elderly, sports and fitness, nutrition and health care, but also promotes the orderly opening of the medical and health field and optimizes the review and approval mechanism for innovative products, laying a solid policy foundation for the health contract manufacturing industry. The deployment of "fostering and expanding health consumption" and "advancing the construction of Healthy China" in the plan has directly driven the explosive demand in segmented fields such as nutrition and health care, medicine and food homology, and special dietary foods. Meanwhile, asset-light operation has become the mainstream model for brands to layout the health market, further releasing the production capacity demand of the contract manufacturing market and promoting the continuous expansion of the industry scale. Data shows that the market size of nutritional food contract manufacturing has grown from approximately 297.9 billion yuan in 2020 to 405.7 billion yuan in 2024, and is expected to reach 645.2 billion yuan by 2029, with sustained release of industrial development potential.

Under policy guidance, the development logic of the health contract manufacturing industry is undergoing profound changes, with "compliance, high quality, and strong innovation" becoming the core competitiveness of the industry. Previously, some small enterprises in the industry suffered from incomplete qualifications and non-standard production. However, with the implementation of the new Measures for the Supervision and Administration of Food Entrusted Production on December 1, 2026, the regulatory environment has been further tightened, and the compliance responsibilities of both entrusting and entrusted parties have been clearly strengthened. Leading contract manufacturing enterprises with complete qualifications and strict quality control will embrace development dividends, and industry concentration will continue to rise. At the same time, the 15th Five-Year Plan emphasizes "strengthening the driving force of scientific and technological innovation" and promotes the in-depth integration of cutting-edge technologies such as artificial intelligence and biological manufacturing with the health industry, pointing out the direction for the empowerment and upgrading of the contract manufacturing industry. Intelligent production, precise R&D, and flexible customization have become the keys to enterprise breakthroughs.

From the perspective of industry development trends, during the 15th Five-Year Plan period, the health contract manufacturing industry will present three core development directions.

First, product diversification and scenario-based development. As consumer groups expand from the "silver-haired group" to teenagers and workplace professionals, health demand shifts from basic nutritional supplements to precise conditioning, snackification, and convenience. Diversified products such as medicine and food homology, functional gummies, and plant-based beverages are highly popular. Meanwhile, customized demand for segmented scenarios such as "the elderly and children", fitness groups, and women's conditioning continues to grow, requiring contract manufacturing enterprises to have full dosage form coverage capabilities.

Second, intelligent and efficient technology. AI-driven R&D, automated production lines, and digital quality control systems are widely used, which not only improve production efficiency and shorten delivery cycles, but also achieve raw material traceability and full transparency in the production process, meeting the high requirements of brand owners for product quality.

Third, parallel development of globalization and compliance. With the global layout of health consumption, contract manufacturing enterprises with international certification qualifications and familiarity with overseas regulations will gain advantages in cross-border e-commerce and international brand cooperation, serving as a solid backing for brands going global.

With more than ten years of deep cultivation in the health contract manufacturing field, Zhengzhou Linnuo Pharmaceutical has always kept pace with national policy guidelines, taking compliance as the foundation and innovation as the driving force, building differentiated competitive advantages in industry changes and becoming a benchmark enterprise meeting the development requirements of the 15th Five-Year Plan. As a high-tech full-industry-chain enterprise integrating R&D, production, sales, and services, Linnuo Pharmaceutical is located in Zhengzhou High-tech Industrial Development Zone, with a production base of over 10,000 square meters and more than 200 production line employees. It has passed a number of authoritative certifications at home and abroad, including US FDA, HACCP, ISO9001, ISO22000, and GMP, and possesses complete qualifications such as customs import and export qualifications, health food filing, and special dietary food filing, laying a solid guarantee for compliant production.

In terms of production capacity and product category layout, Linnuo Pharmaceutical accurately meets the diversified needs of the industry, covering full dosage forms such as solid beverages, compressed tablets, gummies, plant beverages, pastes, substitute teas, pills, and granules. It boasts outstanding daily production capacity: 32 tons of daily extraction of liquid extracts, 150,000 bottles of daily plant beverage production, 1.5 million bags of daily solid beverage production, and 2.6 million pieces of daily compressed tablet production. It can flexibly undertake large and urgent orders while supporting small-batch flexible production, perfectly solving the pain point of "small orders and quick returns" for emerging brands. Relying on in-depth cooperation with domestic authoritative scientific research institutes and traditional Chinese medicine institutions, Linnuo Pharmaceutical has built a complete R&D system and reserved abundant product solutions. It has not only introduced advanced technologies such as gummy embedding but also complied with the consumption trend of clean labels to continuously promote product innovation, providing brand owners with one-stop OEM/ODM services from R&D, production to warehousing, logistics, and drop-shipping, with a daily drop-shipping capacity of over 100,000 pieces. Its products are exported to dozens of countries and regions in Asia, North America, Europe, etc.

The in-depth implementation of the 15th Five-Year Plan has brought unprecedented development opportunities to the health contract manufacturing industry and put forward higher quality requirements. In the future, the industry will completely bid farewell to "homogeneous competition" and enter a new era of "quality competition, innovation competition, and service competition". Only by adhering to the bottom line of compliance, strengthening technological innovation, and optimizing the service system can enterprises stand firm in the industry tide. Upholding the mission of "serving human health" and the corporate culture of "having faith and responsibility", Zhengzhou Linnuo Pharmaceutical will continue to deeply cultivate core fields such as medicine and food homology and nutrition and health care, continuously upgrade intelligent production levels, strengthen R&D and innovation capabilities, and improve the global service network. It will not only achieve its own high-quality development but also play a benchmark role in the industry, empower upstream and downstream brand partners, jointly promote the health contract manufacturing industry to move toward standardization, high-end, and globalization, assist in the implementation of the Healthy China strategy, serve customers with quality, and connect health to hundreds of millions of families.